Stock Ratings / Health Care / GLSI / forecast

RCKT (31) LRMR (50) LYEL (38) BIOA (44) ⌘ Pro Terminal →

Greenwich LifeSciences Inc. (GLSI) 12-Month Stock Forecast & Price Target Cone

$19.00 +3.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Greenwich LifeSciences Inc. (GLSI) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $278.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GLSI)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your GLSI Position Size: $10,000

Shares at $19.00: 526.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $13.69

$7,205

$-2,795 (-27.9%)

12M Consensus BaseTarget $17.55

$9,237

$-763 (-7.6%)

12M Bull Case BreakoutTarget $35.80

$18,842

+$8,842 (+88.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$18	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$34	69%	B
JP MorganUS Large-Cap Research	SELL	$16	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GLSI)

✓Walkthrough of GLSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GLSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.56%▲ RESISTANCE BREAKOUT

2026-10-30O $18.47H $19.00L $17.04C $19.00VOL 174.6K

RES: $18.11SUP: $13.98SMA50: $16.75SMA200: $21.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GLSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GLSI Butterfly Map → + Track GLSI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GLSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GLSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GLSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GLSI)

Health Care Rank #611 of 1016 ⚔️ RCKT vs GLSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GLSI vs. RCKT, LRMR, LYEL, BIOA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Greenwich LifeSciences Inc. (GLSI) ranks #611 by composite RQD confidence (41/100, grade D-) and #528 by equity capitalization ($278.9M). Within this direct 5-issuer industry benchmark cohort, GLSI leads on earnings valuation at N/A trailing P/E, while GLSI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with GLSI at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GLSI ACTIVE Greenwich LifeSciences Inc.	D-	41/100	—	—	-35.0%	+3.77%	$278.9M	Benchmark Subject
RCKT Rocket Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.55%	$278.8M	/rckt-vs-glsi →
LRMR Larimar Therapeutics Inc.	D	50/100	—	—	-35.0%	+5.12%	$277.4M	/lrmr-vs-glsi →
LYEL Lyell Immunopharma Inc.	D-	38/100	—	—	-35.0%	+3.43%	$277.0M	/lyel-vs-glsi →
BIOA BioAge Labs Inc.	D	44/100	—	—	-35.0%	0.00%	$272.6M	/bioa-vs-glsi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799788

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenwich LifeSciences Inc. (GLSI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$9.9M, and free cash flow of -$9.9M (-36.4% YoY). On the balance sheet, GLSI closed FY2025 with $6.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$19.4M	-$9.9M	-$9.9M	$6.2M	—
FY2024 (FY)	2024-12-31	$0	-$17.4M	-$7.3M	-$7.3M	$4.1M	—
FY2023 (FY)	2023-12-31	$0	-$8.9M	-$6.5M	-$6.5M	—	—

3. GLSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Greenwich LifeSciences Inc. (NASDAQ: GLSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $19.00 (+3.77% 1D, market cap $278.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GLSI ranks #611 in composite RQD confidence.

How does GLSI compare to RCKT and LRMR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GLSI carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RCKT (Rocket Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $278.8M) and LRMR (Larimar Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M). Among the 5-stock peer group, GLSI leads on earnings multiple (N/A) while GLSI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GLSI?

Per GLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799788), Greenwich LifeSciences Inc. generated $0 in revenue, -$19.4M in net income, and -$9.9M in free cash flow against $6.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GLSI trading relative to its 50-day, 200-day, and 52-week technical levels?

GLSI last traded at $19.00 (+3.77% on volume of 124,128 shares), positioning the stock +13.43% above its 50-day simple moving average ($16.75) and -11.79% below its 200-day simple moving average ($21.54). Across its 52-week range of $7.78 to $34.10, GLSI sits at the 42.6% percentile with a 14-day RSI of 53.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.62 to $21.38).

GLSI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is GLSI's 12-month stock price target?

Greenwich LifeSciences Inc. (GLSI) carries a 12-month consensus base price target of $17.55 (-7.6% from $19.00), with a bull-case target of $35.8 and a bear-case floor of $13.69.

Is GLSI stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates GLSI D- (Sell — SELL) with an RQD Confidence score of 41/100.

Direct Sub-Reports: GLSI RQD Cockpit GLSI 12M Forecast GLSI Earnings & Move GLSI Dividends & DRIP GLSI Insiders & 13F GLSI Whale Options GLSI Profit Sankey GLSI News & Why